What is uniQure N.V. (QURE)?

uniQure N.V. (QURE) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of QURE?

The current price of QURE is $24.83. Prices are updated in real time on Stocks360.

What is QURE's price-to-earnings (PE) ratio?

QURE's trailing twelve-month PE ratio is -6.15, based on current price and earnings per share data available on Stocks360.

What is QURE's market capitalization?

QURE's market capitalization is $1,722,367,712.00, placing it in the small-cap tier.

uniQure N.V. (QURE)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$24.83

Market Cap

$1.72B

PE (TTM)

-6.15

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.94

Day Range

$23.56 – $25.21

52-wk Range

$8.73 – $68.62

Avg Volume

N/A

Volume

1.82M

uniQure N.V. (QURE) is a publicly traded company in the Healthcare sector. Latest price: $24.83. Market cap $1.72B. Trailing PE -6.15. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $67.69 2026-10-30 · $24.83 (-63.32%)

Earnings

Most Recent

Jul 29, 2026

EPS $-1.22 vs est. $-0.82

Missed by $0.40

Next Earnings

Nov 4, 2026

EPS estimate $-0.92

Proprietary Signals

Signal snapshot temporarily unavailable.

About uniQure N.V.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-6.15×
P/S (TTM)	92.24×
P/B	5.08×
PEG	0.58×
P/FCF (TTM)	-10.70×
EV / EBITDA	-7.58×
EV / Sales	73.49×
Earnings Yield	-15.33%
Free Cash Flow Yield	-9.35%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.37B
Revenue (TTM)	$18.67M
Net Income (TTM)	-$264.10M
Free Cash Flow (TTM)	-$99.61M
Net Debt	-$350.19M
Working Capital	$750.92M
Gross Margin	22.79%
Operating Margin	-1089.06%
Net Margin	-1350.73%
Return on Equity	-111.96%
Return on Invested Capital	-22.48%